Cadence Bank Increases Stock Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Cadence Bank increased its stake in Bristol Myers Squibb by 28.4% in Q3, buying 50,628 shares to hold 229,201 shares worth $10.337 million at the end of the period.
• Several analysts raised targets (Piper Sandler, Barclays, Guggenheim, Wells Fargo among them), but the MarketBeat consensus remains a Hold with a $61 price target (9 Buys, 12 Holds, 1 Sell).
• BMY reported Q results with EPS of $1.26 (missed vs. $1.65 est.) and revenue of $12.50B (beat), set FY2026 guidance of $6.05–6.35 EPS, and pays a $0.63 quarterly dividend (4.3% yield).

Cadence Bank lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 229,201 shares of the biopharmaceutical company's stock after buying an additional 50,628 shares during the quarter. Cadence Bank's holdings in Bristol Myers Squibb were worth $10,337,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of BMY. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb in the second quarter valued at $25,000. Harbor Capital Advisors Inc. increased its position in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 313 shares in the last quarter. Total Investment Management Inc. purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $38,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $40,000. Finally, Bank of Jackson Hole Trust grew its stake in Bristol Myers Squibb by 352.2% during the 3rd quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 810 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BMY has been the subject of a number of research reports. Piper Sandler reiterated an "overweight" rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Barclays assumed coverage on shares of Bristol Myers Squibb in a research report on Thursday, February 19th. They issued an "overweight" rating and a $75.00 price target for the company. Citigroup increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "neutral" rating in a research note on Friday, February 6th. Guggenheim restated a "buy" rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Wells Fargo & Company reiterated an "outperform" rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $61.00.

Bristol Myers Squibb Stock Up 0.1%

Shares of Bristol Myers Squibb stock opened at $59.02 on Friday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The company has a market cap of $120.18 billion, a P/E ratio of 17.11, a PEG ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The firm has a fifty day moving average of $58.24 and a two-hundred day moving average of $51.40.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company's revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.